nkx019
nkx019: developed by 1 company · 4 clinical trials tracked.
nkx019 evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
How could nkx019 → NKTX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Nkarta, Inc. (NKTX) Lupus Nephritis; Systemic Sclerosis; Lymphoma, Non-Hodgkin | Phase 1/Phase 2 |
Clinical Trials (4)
A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Immune-Mediated Diseases
Primary endpoint: Incidence of Dose-limiting toxicities (DLTs) [Safety and Tolerability]
A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Systemic Lupus Erythematosus
Primary endpoint: Incidence of adverse events (AEs)
A Phase 1/2 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Autoimmune Disease
Primary endpoint: Incidence of dose-limiting toxicities (DLTs) [Safety and Tolerability]
A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With B-cell Malignancies
Primary endpoint: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Frequently asked questions
Who is developing nkx019?
nkx019 is being developed by Nkarta, Inc..
How many clinical trials involve nkx019?
BioSniper tracks 4 clinical trials involving nkx019.